Structural elucidation of recombinant Trichomonas vaginalis 20S proteasome bound to covalent inhibitors
Silhan, J.; Fajtova, P.; Bartosova, J.; Hurysz, B.; Almaliti, J.; Miyamoto, Y.; Eckmann, L.; Gerwick, W.; O Donoghue, A.; Boura, E.
Show abstract
Proteasomes are essential for protein homeostasis in mammalian cells1-4 and in protozoan parasites such as Trichomonas vaginalis (Tv).5 Tv and other protozoan 20S proteasomes have been validated as druggable targets.6-8 However, in the case of Tv 20S proteasome (Tv20S), biochemical and structural studies were impeded by low yields and purity of the native proteasome. We successfully made recombinant Tv20S by expressing all seven and seven {beta} subunits together with the Ump-1 chaperone in insect cells. We isolated recombinant proteasome and showed that it was biochemically indistinguishable from the native enzyme. We confirmed that the recombinant Tv20S is inhibited by the natural product marizomib (MZB)9 and the recently developed peptide inhibitor carmaphycin-17 (CP-17)8,10. Specifically, MZB binds to the {beta}1, {beta}2 and {beta}5 subunits, while CP-17 binds the {beta}2 and {beta}5 subunits. Next, we obtained cryo-EM structures of Tv20S in complex with these covalent inhibitors at 2.8[A] resolution. The structures revealed the overall fold of the Tv20S and the binding mode of MZB and CP-17. Our work explains the low specificity of MZB and higher specificity of CP-17 towards Tv20S as compared to human proteasome and provides the platform for the development of Tv20S inhibitors for treatment of trichomoniasis.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Conformational plasticity across phylogenetic clusters of RND multidrug efflux pumps and its impact on substrate specificity 95%
- Structures of native SV2A reveal the binding mode for tetanus neurotoxin and anti-epileptic racetams 94%
- Conformational maps of human 20S proteasomes reveal PA28- and immuno-dependant inter-ring crosstalks 94%
Similar papers in this journal
Similar papers in this journal
- Bromodomain Factor 5 as a Target for Antileishmanial Drug Discovery 94%
- Structural basis for postfusion-specific binding to Respiratory Syncytial Virus F protein by the canonical antigenic site I antibody 131-2a 93%
- Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19 93%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.